Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
DE:69C
Stock Latest News
The Fly
Tvardi announces publication of preclinical data on STAT3 inhibitor
9d ago
TVRD
Premium
The Fly
Tvardi Therapeutics assumed with a Buy at Lucid Capital
25d ago
TVRD
Premium
Ratings
Tvardi Maintained at Buy as Analyst Highlights Differentiated STAT3 Approach in UC; Price Target Reaffirmed at $9
1M ago
TVRD
Premium
Ratings
Analyst Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5 on Updated Assumptions and Funding Needs
2M ago
TVRD
Premium
The Fly
Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)
2M ago
TVRD
Premium
Ratings
Tvardi: Strategic Pivot to Ulcerative Colitis and Upcoming HCC Readouts Support Unchanged $9 Price Target and Buy Rating
2M ago
TVRD
Premium
The Fly
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
2M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Targets Ulcerative Colitis With STAT3 Inhibitor
2M ago
8K
TVRD
Premium
Company Announcements
Tvardi Therapeutics Expands At-The-Market Equity Program
3M ago
8K
TVRD
Premium
The Fly
Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
3M ago
TVRD
Premium
The Fly
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
3M ago
TVRD
Premium
The Fly
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
3M ago
TVRD
Premium
The Fly
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
3M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Reports Phase 1 Data for TTI-109
3M ago
8K
TVRD
Premium
Company Announcements
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures
4M ago
8K
TVRD
Premium
The Fly
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
4M ago
TVRD
Premium
The Fly
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
5M ago
TVRD
Premium
The Fly
Tvardi Therapeutics files $200M mixed securities shelf
5M ago
TVRD
Premium
The Fly
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
6M ago
TVRD
Premium
Ratings
Buy Rating on Tvardi: Differentiated STAT3 Platform, Upcoming TTI-109/TTI-101 Catalysts, and Attractive Risk‑Reward Through 2026
6M ago
TVRD
Premium
Company Announcements
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development
6M ago
TVRD
Premium
The Fly
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
6M ago
TVRD
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
